Human Vaccines & Immunotherapeutics (Jun 2019)

Vaccine coverage and compliance in Mexico with the two-dose and three-dose rotavirus vaccines

  • Gerardo Luna-Casas,
  • Patricia Juliao,
  • Roberto Carreño-Manjarrez,
  • Andrés Castañeda-Prado,
  • Maria Yolanda Cervantes-Apolinar,
  • Ricardo Navarro-Rodriguez,
  • Gilberto Sánchez-González,
  • Ricardo Cortés-Alcalá,
  • Rodrigo DeAntonio

DOI
https://doi.org/10.1080/21645515.2018.1540827
Journal volume & issue
Vol. 15, no. 6
pp. 1251 – 1259

Abstract

Read online

Worldwide, rotavirus infection has been a leading cause of severe diarrhea morbidity and mortality. Two rotavirus vaccines have been used in the National Immunization Program (NIP) in Mexico; two-dose Rotarix from 2006 to 2011 and three-dose RotaTeq since 2011. This study assessed coverage (receiving at least one dose or full dose series) in eligible infants, compliance (% completing dose series and % completing series on schedule) in eligible infants vaccinated with Rotarix (2010) versus RotaTeq (2012), using Mexican Social Security Institute data nationwide and by regions. In 2010, 80.7% received at least one dose of Rotarix, 75.6% received both doses and 57.0% received both doses on schedule. In 2012, 85.7% received at least one dose of RotaTeq, 61.0% received all three doses and 43.2% received all three doses on schedule. More eligible infants received all doses with Rotarix versus RotaTeq (p < 0.001). Among infants vaccinated with Rotarix versus RotaTeq, 93.7% versus 71.1% completed full series (p < 0.001), and 75.5% versus 70.9% completed full series on schedule (p = 0.105), respectively. The full series coverage and compliance decreased in all regions with RotaTeq compared with Rotarix. In conclusion, rotavirus vaccination has successfully reduced morbidity and mortality in children under 5 years in Mexico. This study found significant differences in full series coverage and compliance among infants and a higher proportion of completed scheduled at an earlier age in Mexico when comparing a two-dose vaccine in 2010 with a three-dose vaccine in 2012. Such differences might need to be taken into consideration to maximize NIP benefits, including early protection of the rotavirus vaccination program.

Keywords